Novel estrogen receptor beta agonist S-equol decreases tumor proliferation in patients with triple negative breast cancer (TNBC).Kate Lathrop, Richard Elledge, Virginia Kaklamani et al.|Journal of Clinical Oncology|2020Cited by 12
Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort studyGayathri Nagaraj, Gary H. Lyman, Poorva Bindal et al.|eLife|2023Cited by 3
Abstract PS5-31: Molecular markers of response to s-equol, a novel oral estrogen receptor (ER) beta agonist for triple negative breast cancerKate Lathrop, Richard Elledge, Virginia Kaklamani et al.|Cancer Research|2021Cited by 2
Correlation between Oncotype Dx score with histologic grade, tumor size and Ki67 in patients with early stage breast cancer: A single academic institution experience.Kate Lathrop, Katherine A Terracina, Marcela Mazo Canola et al.|Journal of Clinical Oncology|2015Cited by 1
Correlation between Oncotype DX score with histologic grade, tumor size and Ki67 in patients with early stage breast cancer: A single academic institution experience.Kate Lathrop, Katherine A Terracina, Marcela Mazo Canola et al.|Journal of Clinical Oncology|2015Cited by 1